Author Archives: Marisa Wexler, MS

Alpine, Evotec Expanding Production of ALPN-303, Potential Therapy

Alpine Immune Sciences and Evotec announced the expansion of an agreement to manufacture ALPN-303, an experimental anti-inflammatory therapy that Alpine is developing for systemic lupus erythematosus (SLE) and other diseases driven by immune B-cells. Under the initial 2020 agreement, Evotec’s subsidiary Just-Evotec Biologics used its continuous manufacturing…

FDA Approves Benlysta for Children With Active Lupus Nephritis

The U.S. Food and Drug Administration (FDA) has extended the use of Benlysta (belimumab), given on top of standard therapy, to treat children ages 5 to 17 with active lupus nephritis, a serious form of kidney inflammation caused by lupus. Benlysta is the first FDA-approved treatment for pediatric lupus…

Black Women with SLE Find Self-Management Program Improves Health

An educational program done in small, local, and peer-led groups, called the Chronic Disease Self‐Management Program, was seen as helpful by African-American women with systemic lupus erythematosus (SLE), improving their diet, ability to exercise, and their adherence to treatment, a study suggests. The study, “Exploring…